Illumina Signs Multiple Biobank Deals
News Feb 09, 2016
Illumina, Inc. has announced it has signed four separate biobanking deals with Vanderbilt University, University of Colorado at Anschutz Medical Campus, Partners HealthCare, and Montreal Heart Institute to advance personalized medicine and improve health care. Under the agreements, the large sample collections housed at each institution will be genotyped using Illumina technologies. By combining genomic information with electronic medical records and clinical information, the institutions hope to accelerate discoveries that will improve human health.
The Infinium® Expanded Multi-Ethnic Genotyping Array, Infinium HumanMethylation 450K Array and Illumina sequencing systems will be used to analyze an initial 200,000 samples and gain insight into the underlying genetic factors that may contribute to heart disease, cancer, Alzheimer’s, bipolar disorder, and Crohn’s disease, among many other complex diseases.
“These four personalized medicine programs represent progressive examples of how characterizing the genome using multiple genetic analysis solutions is significantly advancing the understanding of human biology. These programs are at the forefront of translational research and the clinical application of genomic data,” said Illumina Executive Vice President and Chief Commercial Officer, Christian Henry.